Sirius Capital
Biotech, portfolio strategy, long/short equity, small-mid cap

How Do Recent Developments In The Approval Process For Heplisav-B By Dynavax Affect The Chances For A Positive PDUFA?

Inroduction Dynavax (NASDAQ:DVAX) is developing Heplisav-B, a new vaccine for HBV (Hepatitis B virus) prevention. This vaccine utilizes a novel mechanism for stimulating the immune system which will allow the vaccine to protect from infection after two vaccinations, 4 weeks apart. This is a simpler vaccination regime than that of the standard-of-care vaccines like Engerix-B by GlaxoSmithKline (NYSE:GSK) that require 3 vaccinations with the last being 6 months after the first. We reviewed this drug development program in an SA article last August while we were anticipating results of a large scale trial with 8,000 patients that was designed to remove doubts about the safety of the treatment. The company was also reviewed recently by Bhavneesh ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details